Streetbeat News

Analyst Ratings

MIRM

Citigroup analyst David Lebowitz maintains a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $38 to $64.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:43 pm

SUN

Citigroup analyst Spiro Dounis has upgraded Sunoco (NYSE:SUN) from Neutral to Buy and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:39 pm

CEG

UBS analyst Ross Fowler maintains a Buy rating on Constellation Energy (NASDAQ:CEG) and raises the price target from $227 to $249.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:33 pm

CATX

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Perspective Therapeutics (AMEX:CATX) and adjusted the price target to $19 from $2 following a 10-1 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:32 pm

TER

UBS analyst Timothy Arcuri maintains a Buy rating on Teradyne (NASDAQ:TER) and raises the price target from $130 to $170.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:31 pm

DELL

Dell Technologies shares are trading higher following a bullish note from Morgan Stanley.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:31 pm

CELH

Deep-pocketed investors have shown a bearish sentiment towards Celsius Holdings (NASDAQ:CELH) based on significant options activity. The majority of the options trades detected were bearish, with a notable volume and open interest in both puts and calls. Analysts have mixed ratings, with a consensus target price of $87.8.

Portfolio Pulse from Benzinga Insights

June 18, 2024 | 2:31 pm

DIS

Recent options activity for Walt Disney (NYSE:DIS) shows a mixed sentiment among investors, with significant trades indicating both bullish and bearish expectations. The stock is currently trading at $101.01, down by 0.5%, with a neutral RSI. Analysts have a consensus target price of $100.0.

Portfolio Pulse from Benzinga Insights

June 18, 2024 | 2:31 pm

AVTE

Wells Fargo analyst Tiago Fauth has downgraded Aerovate Therapeutics (NASDAQ:AVTE) from Overweight to Equal-Weight and significantly lowered the price target from $35 to $2.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:28 pm